Brimonidine tartarate - Ocugen

Drug Profile

Brimonidine tartarate - Ocugen

Alternative Names: OCU 300

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Illinois at Chicago
  • Developer Ocugen
  • Class Antiglaucomas; Antihypertensives; Quinoxalines
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Graft-versus-host disease

Most Recent Events

  • 17 Aug 2017 Chemical structure information added
  • 09 Aug 2017 Brimonidine tartarate receives Orphan Drug status for Graft-versus-host disease in USA
  • 11 Feb 2016 Phase-II/III clinical trials in Ocular Graft-versus-host disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top